Compare · AGL vs CCEL
AGL vs CCEL
Side-by-side comparison of agilon health inc. (AGL) and Cryo-Cell International Inc. (CCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and CCEL operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- AGL is the larger of the two at $1.64B, about 19.6x CCEL ($83.3M).
- Over the past year, AGL is up 89.2% and CCEL is down 30.4% - AGL leads by 119.6 points.
- AGL has been more active in the news (4 items in the past 4 weeks vs 2 for CCEL).
- AGL has more recent analyst coverage (25 ratings vs 0 for CCEL).
- Company
- agilon health inc.
- Cryo-Cell International Inc.
- Price
- $97.67-1.63%
- $3.41-3.94%
- Market cap
- $1.64B
- $83.3M
- 1M return
- -8.42%
- -7.21%
- 1Y return
- +89.17%
- -30.41%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2022
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 0
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Latest AGL
- agilon health downgraded by Citigroup with a new price target
- agilon health inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- agilon health Sets Date to Report Second Quarter 2026 Financial Results
- Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 2,311 shares, decreasing direct ownership by 2% to 138,031 units (SEC Form 4) to satisfy tax liability
- agilon health to Participate in Upcoming Conferences
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 485 shares, decreasing direct ownership by 0.73% to 66,112 units (SEC Form 4) (tax liability)
- Director Wulf John William was granted 2,133 shares, increasing direct ownership by 15% to 16,765 units (SEC Form 4)
- Director Williams Ronald A was granted 2,133 shares, increasing direct ownership by 1% to 149,141 units (SEC Form 4)
- Director Mcloughlin Karen was granted 2,133 shares, increasing direct ownership by 35% to 8,207 units (SEC Form 4)
- Director Mckenzie Diana was granted 2,133 shares, increasing direct ownership by 39% to 7,633 units (SEC Form 4)
Latest CCEL
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
- Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice